{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:29:17Z","timestamp":1707524957592},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,28]]},"DOI":"10.7759\/cureus.36834","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T05:26:32Z","timestamp":1680067592000},"source":"Crossref","is-referenced-by-count":0,"title":["Daptomycin-Rifampin-Induced Rhabdomyolysis, Acute Renal Failure, and Hepatic Injury: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Venu M","family":"Ganipisetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Dudiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Athavale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratyusha","family":"Bollimunta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babu Sriram","family":"Maringanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu C","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al.. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011, 52:285-92. 10.1093\/cid\/cir034","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01746-18","article-title":"Role of rifampin against staphylococcal biofilm infections in vitro, in animal models, and in orthopedic-device-related infections","volume":"63","author":"Zimmerli W","year":"2019","unstructured":"Zimmerli W, Sendi P. Role of rifampin against staphylococcal biofilm infections in vitro, in animal models, and in orthopedic-device-related infections. Antimicrob Agents Chemother. 2019, 63:10.1128\/AAC.01746-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit AK","year":"2019","unstructured":"Thabit AK, Fatani DF, Bamakhrama MS, Barnawi OA, Basudan LO, Alhejaili SF. Antibiotic penetration into bone and joints: an updated review. Int J Infect Dis. 2019, 81:128-36. 10.1016\/j.ijid.2019.02.005","journal-title":"Int J Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2010.08.009","article-title":"Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection","volume":"40","author":"Cirioni O","year":"2010","unstructured":"Cirioni O, Mocchegiani F, Ghiselli R, et al.. Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection. Eur J Vasc Endovasc Surg. 2010, 40:817-22. 10.1016\/j.ejvs.2010.08.009","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.07.001","article-title":"Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia","volume":"71","author":"Kelesidis T","year":"2011","unstructured":"Kelesidis T, Humphries R, Ward K, Lewinski MA, Yang OO. Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia. Diagn Microbiol Infect Dis. 2011, 71:286-90. 10.1016\/j.diagmicrobio.2011.07.001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx349","article-title":"Daptomycin","volume":"73","author":"Heidary M","year":"2018","unstructured":"Heidary M, Khosravi AD, Khoshnood S, Nasiri MJ, Soleimani S, Goudarzi M. Daptomycin. J Antimicrob Chemother. 2018, 73:1-11. 10.1093\/jac\/dkx349","journal-title":"J Antimicrob Chemother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29764","article-title":"Daptomycin-related rhabdomyolysis complicated by severe hyperkalemia and acute kidney injury","volume":"14","author":"Nishimura Y","year":"2022","unstructured":"Nishimura Y. Daptomycin-related rhabdomyolysis complicated by severe hyperkalemia and acute kidney injury. Cureus. 2022, 14:e29764. 10.7759\/cureus.29764","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2014.901555","article-title":"Daptomycin-induced rhabdomyolysis and acute liver injury","volume":"46","author":"King ST","year":"2014","unstructured":"King ST, Walker ED, Cannon CG, Finley RW. Daptomycin-induced rhabdomyolysis and acute liver injury. Scand J Infect Dis. 2014, 46:537-40. 10.3109\/00365548.2014.901555","journal-title":"Scand J Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki476","article-title":"Rhabdomyolysis and acute renal failure in a patient treated with daptomycin","volume":"57","author":"Kazory A","year":"2006","unstructured":"Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother. 2006, 57:578-9. 10.1093\/jac\/dki476","journal-title":"J Antimicrob Chemother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.07.009","article-title":"Early-onset rhabdomyolysis related to daptomycin use","volume":"30","author":"Patel SJ","year":"2007","unstructured":"Patel SJ, Samo TC, Suki WN. Early-onset rhabdomyolysis related to daptomycin use. Int J Antimicrob Agents. 2007, 30:472-4. 10.1016\/j.ijantimicag.2007.07.009","journal-title":"Int J Antimicrob Agents"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K579","article-title":"Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis","volume":"42","author":"Abraham G","year":"2008","unstructured":"Abraham G, Finkelberg D, Spooner LM. Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis. Ann Pharmacother. 2008, 42:719-21. 10.1345\/aph.1K579","journal-title":"Ann Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.8.1223","article-title":"Daptomycin: a novel agent for Gram-positive infections","volume":"8","author":"Tally FP","year":"1999","unstructured":"Tally FP, Zeckel M, Wasilewski MM, Carini C, Berman CL, Drusano GL, Oleson FB Jr. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs. 1999, 8:1223-38. 10.1517\/13543784.8.8.1223","journal-title":"Expert Opin Investig Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"38","author":"Arbeit RD","year":"2004","unstructured":"Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004, 38:1673-81. 10.1086\/420818","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000109868","article-title":"Daptomycin: a review 4 years after first approval","volume":"81","author":"Sauermann R","year":"2008","unstructured":"Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology. 2008, 81:79-91. 10.1159\/000109868","journal-title":"Pharmacology"},{"key":"ref15","article-title":"Daptomycin and incidence of elevated creatinine phosphokinase (CPK) levels: a case report and case series review","volume":"72","author":"Kishimoto E","year":"2013","unstructured":"Kishimoto E, Ota L, Solomon C. Daptomycin and incidence of elevated creatinine phosphokinase (CPK) levels: a case report and case series review. Hawaii J Med Public Health. 2013, 72:42.","journal-title":"Hawaii J Med Public Health"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1298","article-title":"Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States","volume":"33","author":"Bookstaver PB","year":"2013","unstructured":"Bookstaver PB, Bland CM, Qureshi ZP, Faulkner-Fennell CM, Sheldon MA, Caulder CR, Hartis C. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Pharmacotherapy. 2013, 33:1322-30. 10.1002\/phar.1298","journal-title":"Pharmacotherapy"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann A","year":"2008","unstructured":"Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008, 23:192-202. 10.1111\/j.1440-1746.2007.05207.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-013-1856-y","article-title":"The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections","volume":"37","author":"Jugun K","year":"2013","unstructured":"Jugun K, Vaudaux P, Garbino J, Pagani L, Hoffmeyer P, Lew D, U\u00e7kay I. The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections. Int Orthop. 2013, 37:1375-80. 10.1007\/s00264-013-1856-y","journal-title":"Int Orthop"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/146634-daptomycin-rifampin-induced-rhabdomyolysis-acute-renal-failure-and-hepatic-injury-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:12Z","timestamp":1707508752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/146634-daptomycin-rifampin-induced-rhabdomyolysis-acute-renal-failure-and-hepatic-injury-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.36834","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}